Tripla negatív emlőrák: vizsgálatok itt: Románia
4 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Where
- Bucharest, Cluj-Napoca, Comuna Floresti, Craiova, Ploieşti, Timișoara
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00 - 3. fázisTaking peopleA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Where
- Bucharest, Cluj-Napoca, Floresti, Iași, Timisoara
- Életkor
- 18 év and over
- People
- 2400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00 - 1/2. fázisTaking peopleFirst in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Where
- Bucharest, Cluj-Napoca
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06657222 · EU 2025-522517-35-00 - 2/3. fázisTaking peopleA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Where
- Bistrița-Năsăud, Bucharest, Cluj-Napoca, Craiova, Floresti, Iasi, Iași, Ploieşti, Timis, Timisoara
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00